Lexeo Therapeutics, Inc. (LXEO)
(Real Time Quote from BATS)
$15.25 USD
+0.09 (0.59%)
Updated May 23, 2024 02:12 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
LXEO 15.25 +0.09(0.59%)
Will LXEO be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for LXEO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for LXEO
What Makes Lexeo Therapeutics, Inc. (LXEO) a New Buy Stock
Wall Street Analysts Think Lexeo Therapeutics, Inc. (LXEO) Could Surge 57.82%: Read This Before Placing a Bet
LXEO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for LXEO
Analysts Offer Insights on Healthcare Companies: Lexeo Therapeutics, Inc. (LXEO), RAPT Therapeutics (RAPT) and Hookipa Pharma (HOOK)
RBC Capital Remains a Buy on Lexeo Therapeutics, Inc. (LXEO)
Lexeo Therapeutics reports Q1 results
Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights
Lexeo Therapeutics reports Q1 EPS (77c), consensus (77c)